Abstract
e18921Background: Abiraterone (abi) and enzalutamide (enza) are costly drugs which extend the lives of prostate cancer patients, but endpoints for clinical progression are unclear. We studied treat...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have